ARTICLE | Clinical News
Amonafide: Phase III amend
October 19, 2009 7:00 AM UTC
Antisoma will amend the ongoing, open-label Phase III ACCEDE trial evaluating AS1413 to change the primary endpoint to initial remission rate from confirmed remission (CR) rate in order to remove the ...